HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Legend Biotech Analyst Ratings
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Legend Biotech Price Target Maintained With a $86.00/Share by RBC Capital
Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $76
Legend Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Strong Market Acceptance and Strategic Growth Potential Justify Buy Rating for Legend Biotech
Barclays Sticks to Their Buy Rating for Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Staar Surgical (STAA) and Organon (OGN)
Legend Biotech (LEGN) Gets a Hold From William Blair
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating on Legend Biotech: Strong Carvykti Sales and High Market Potential Signal Upside
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Legend Biotech Analyst Ratings
The Latest Analyst Ratings For Legend Biotech
Legend Biotech Analyst Ratings
TD Cowen Maintains Buy on Legend Biotech, Lowers Price Target to $67
Truist Financial Remains a Buy on Legend Biotech (LEGN)